Lexington Biosciences Inc. (CSE:LNB) (OTC:LXGTF) plans to commercialize an at-home product to better predict whether a person is at risk for cardiovascular disease Angela Harmantas | May 31, 2018 | SmallCapPower: Cardiovascular disease is leading cause of death in North America, and yet, nearly one-third of those deaths are preventable. Annually, over 1.5 million people
Lexington Biosciences, Inc.’s (CSE:LNB) Donald McInnes discusses the Company’s regulatory and commercialization efforts Lexington Biosciences Founder: We Have a Cardiovascular Disease Prediction Device In an interview with SmallCapPower, Lexington Biosciences, Inc. (CSE:LNB) Founder and Board Advisor Donald McInnes explains that Lexington’s technology helps predict cardiovascular disease, which is known as the “silent killer.” Find out more about
By David Godkin, Staff Writer – BioWorld MedTech — Volume 22, No. 28 — February 9, 2018 Its investigative team nearly in place, Vancouver-based Lexington Biosciences Inc. will shortly begin enrolling volunteers in a pilot study to test the Heartsentry device. The device measures the viability of the endothelium, those cells lining our arteries and
Story highlight Heart disease and cancer are the top two killers of Americans (CNN)The leading causes of death remained the same from the year before: Heart disease is the No. 1 killer, followed by cancer, according to the U.S. Centers for Disease Control and Prevention, and infant mortality decreased 2.3%. But there is good news